vs
拜玛林制药（BMRN）与NORTHERN OIL & GAS, INC.（NOG）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是NORTHERN OIL & GAS, INC.的1.4倍（$874.6M vs $610.2M），拜玛林制药净利率更高（-5.3% vs -11.6%，领先6.3%），拜玛林制药同比增速更快（17.0% vs -72.6%），拜玛林制药自由现金流更多（$58.9M vs $43.2M），过去两年拜玛林制药的营收复合增速更高（16.1% vs 4.3%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
Marathon Oil Corporation是一家美国油气勘探开发企业，核心业务涵盖油气资源的勘探、开采与运营，2024年11月被康菲石油收购，相关业务与资产已并入康菲石油体系。
BMRN vs NOG — 直观对比
营收规模更大
BMRN
是对方的1.4倍
$610.2M
营收增速更快
BMRN
高出89.6%
-72.6%
净利率更高
BMRN
高出6.3%
-11.6%
自由现金流更多
BMRN
多$15.7M
$43.2M
两年增速更快
BMRN
近两年复合增速
4.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $610.2M |
| 净利润 | $-46.6M | $-70.7M |
| 毛利率 | 68.5% | — |
| 营业利润率 | -5.1% | — |
| 净利率 | -5.3% | -11.6% |
| 营收同比 | 17.0% | -72.6% |
| 净利润同比 | -137.3% | -198.7% |
| 每股收益（稀释后） | $-0.22 | $-0.73 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNNOG
| Q1 26 | — | $610.2M | ||
| Q4 25 | $874.6M | $610.2M | ||
| Q3 25 | $776.1M | $556.6M | ||
| Q2 25 | $825.4M | $706.8M | ||
| Q1 25 | $745.1M | $602.1M | ||
| Q4 24 | $747.3M | $515.0M | ||
| Q3 24 | $745.7M | $753.6M | ||
| Q2 24 | $712.0M | $560.8M |
净利润BMRNNOG
| Q1 26 | — | $-70.7M | ||
| Q4 25 | $-46.6M | $-70.7M | ||
| Q3 25 | $-30.7M | $-129.1M | ||
| Q2 25 | $240.5M | $99.6M | ||
| Q1 25 | $185.7M | $139.0M | ||
| Q4 24 | $124.9M | $71.7M | ||
| Q3 24 | $106.1M | $298.4M | ||
| Q2 24 | $107.2M | $138.6M |
毛利率BMRNNOG
| Q1 26 | — | — | ||
| Q4 25 | 68.5% | 80.4% | ||
| Q3 25 | 82.0% | 78.7% | ||
| Q2 25 | 81.8% | 82.8% | ||
| Q1 25 | 79.7% | 81.1% | ||
| Q4 24 | 81.8% | 77.4% | ||
| Q3 24 | 74.7% | 85.8% | ||
| Q2 24 | 81.7% | 82.0% |
营业利润率BMRNNOG
| Q1 26 | — | — | ||
| Q4 25 | -5.1% | -5.5% | ||
| Q3 25 | -6.0% | -22.6% | ||
| Q2 25 | 33.5% | 24.9% | ||
| Q1 25 | 30.0% | 38.1% | ||
| Q4 24 | 21.6% | 25.8% | ||
| Q3 24 | 15.3% | 57.6% | ||
| Q2 24 | 16.9% | 39.0% |
净利率BMRNNOG
| Q1 26 | — | -11.6% | ||
| Q4 25 | -5.3% | -11.6% | ||
| Q3 25 | -4.0% | -23.2% | ||
| Q2 25 | 29.1% | 14.1% | ||
| Q1 25 | 24.9% | 23.1% | ||
| Q4 24 | 16.7% | 13.9% | ||
| Q3 24 | 14.2% | 39.6% | ||
| Q2 24 | 15.1% | 24.7% |
每股收益（稀释后）BMRNNOG
| Q1 26 | — | $-0.73 | ||
| Q4 25 | $-0.22 | $-0.67 | ||
| Q3 25 | $-0.16 | $-1.33 | ||
| Q2 25 | $1.23 | $1.00 | ||
| Q1 25 | $0.95 | $1.39 | ||
| Q4 24 | $0.65 | $0.71 | ||
| Q3 24 | $0.55 | $2.96 | ||
| Q2 24 | $0.55 | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $14.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.1B | $2.1B |
| 总资产 | $7.6B | $5.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRNNOG
| Q1 26 | — | $14.3M | ||
| Q4 25 | $1.3B | $14.3M | ||
| Q3 25 | $1.3B | $31.6M | ||
| Q2 25 | $1.2B | $25.9M | ||
| Q1 25 | $1.0B | $33.6M | ||
| Q4 24 | $942.8M | $8.9M | ||
| Q3 24 | $675.4M | $34.4M | ||
| Q2 24 | $972.1M | $7.8M |
总债务BMRNNOG
| Q1 26 | — | — | ||
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.4B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.0B | ||
| Q2 24 | — | $1.9B |
股东权益BMRNNOG
| Q1 26 | — | $2.1B | ||
| Q4 25 | $6.1B | $2.1B | ||
| Q3 25 | $6.1B | $2.2B | ||
| Q2 25 | $6.0B | $2.4B | ||
| Q1 25 | $5.8B | $2.4B | ||
| Q4 24 | $5.7B | $2.3B | ||
| Q3 24 | $5.4B | $2.3B | ||
| Q2 24 | $5.3B | $2.1B |
总资产BMRNNOG
| Q1 26 | — | $5.4B | ||
| Q4 25 | $7.6B | $5.4B | ||
| Q3 25 | $7.6B | $5.5B | ||
| Q2 25 | $7.5B | $5.7B | ||
| Q1 25 | $7.1B | $5.7B | ||
| Q4 24 | $7.0B | $5.6B | ||
| Q3 24 | $6.9B | $5.1B | ||
| Q2 24 | $7.1B | $4.7B |
负债/权益比BMRNNOG
| Q1 26 | — | — | ||
| Q4 25 | — | 1.13× | ||
| Q3 25 | — | 1.05× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.91× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $312.6M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $43.2M |
| 自由现金流率自由现金流/营收 | 6.7% | 7.1% |
| 资本支出强度资本支出/营收 | 4.7% | 31.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | — |
8季度趋势，按日历期对齐
经营现金流BMRNNOG
| Q1 26 | — | $312.6M | ||
| Q4 25 | $99.6M | $312.6M | ||
| Q3 25 | $368.7M | $423.1M | ||
| Q2 25 | $185.3M | $362.1M | ||
| Q1 25 | $174.4M | $407.4M | ||
| Q4 24 | $185.6M | $290.3M | ||
| Q3 24 | $221.5M | $385.8M | ||
| Q2 24 | $118.8M | $340.5M |
自由现金流BMRNNOG
| Q1 26 | — | $43.2M | ||
| Q4 25 | $58.9M | — | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $168.2M | — | ||
| Q1 25 | $157.6M | — | ||
| Q4 24 | $166.1M | — | ||
| Q3 24 | $203.0M | — | ||
| Q2 24 | $97.4M | — |
自由现金流率BMRNNOG
| Q1 26 | — | 7.1% | ||
| Q4 25 | 6.7% | — | ||
| Q3 25 | 43.8% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 22.2% | — | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 13.7% | — |
资本支出强度BMRNNOG
| Q1 26 | — | 31.5% | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.0% | — |
现金转化率BMRNNOG
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.77× | 3.64× | ||
| Q1 25 | 0.94× | 2.93× | ||
| Q4 24 | 1.49× | 4.05× | ||
| Q3 24 | 2.09× | 1.29× | ||
| Q2 24 | 1.11× | 2.46× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
NOG
| Oil and Gas Sales | $447.7M | 73% |
| Gain on Commodity Derivatives, Net | $159.3M | 26% |
| Other Revenue | $3.1M | 1% |
